Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
AIMM Therapeutics B.V. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AIMM Therapeutics B.V. - Product Pipeline Review - 2014', provides an overview of the AIMM Therapeutics B.V.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of AIMM Therapeutics B.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of AIMM Therapeutics B.V. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of AIMM Therapeutics B.V.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the AIMM Therapeutics B.V.'s pipeline products Reasons to buy - Evaluate AIMM Therapeutics B.V.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of AIMM Therapeutics B.V. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the AIMM Therapeutics B.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of AIMM Therapeutics B.V. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of AIMM Therapeutics B.V. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of AIMM Therapeutics B.V. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 AIMM Therapeutics B.V. Snapshot 5 AIMM Therapeutics B.V. Overview 5 Key Information 5 Key Facts 5 AIMM Therapeutics B.V. - Research and Development Overview 6 Key Therapeutic Areas 6 AIMM Therapeutics B.V. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 AIMM Therapeutics B.V. - Pipeline Products Glance 11 AIMM Therapeutics B.V. - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 AIMM Therapeutics B.V. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 AIMM Therapeutics B.V. - Drug Profiles 14 Monoclonal Antibodies for Seasonal Influenza 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Bispecific Monoclonal Antibodies for Seasonal and Pandemic Influenza 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Monoclonal Antibodies for Gastrointestinal Diseases 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Monoclonal Antibodies for MRSA Infections 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Monoclonal Antibodies for Respiratory Syncytial Virus Infections 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Monoclonal Antibodies for AML 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Monoclonal Antibodies for Clostridium Dificile Infections 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Monoclonal Antibodies for Cytomegalo Virus Infections 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Monoclonal Antibodies for HCV 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Monoclonal Antibodies for Melanoma 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Monoclonal Antibodies for Parecho Virus Infections 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 AIMM Therapeutics B.V. - Pipeline Analysis 25 AIMM Therapeutics B.V. - Pipeline Products by Target 25 AIMM Therapeutics B.V. - Pipeline Products by Route of Administration 26 AIMM Therapeutics B.V. - Pipeline Products by Molecule Type 27 AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action 28 AIMM Therapeutics B.V. - Recent Pipeline Updates 29 AIMM Therapeutics B.V. - Dormant Projects 30 AIMM Therapeutics B.V. - Locations And Subsidiaries 31 Head Office 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 33 Disclaimer 33
List of Tables AIMM Therapeutics B.V., Key Information 5 AIMM Therapeutics B.V., Key Facts 5 AIMM Therapeutics B.V. - Pipeline by Indication, 2014 8 AIMM Therapeutics B.V. - Pipeline by Stage of Development, 2014 9 AIMM Therapeutics B.V. - Monotherapy Products in Pipeline, 2014 10 AIMM Therapeutics B.V. - Phase I, 2014 11 AIMM Therapeutics B.V. - Preclinical, 2014 12 AIMM Therapeutics B.V. - Discovery, 2014 13 AIMM Therapeutics B.V. - Pipeline by Target, 2014 25 AIMM Therapeutics B.V. - Pipeline by Route of Administration, 2014 26 AIMM Therapeutics B.V. - Pipeline by Molecule Type, 2014 27 AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action, 2014 28 AIMM Therapeutics B.V. - Recent Pipeline Updates, 2014 29 AIMM Therapeutics B.V. - Dormant Developmental Projects,2014 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
